Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin--a preliminary report.

Y Levy1, Y Sherer, P Langevitz

  • 1Department of Medicine B, Sheba Medical Center, Tel-Aviv University, Israel.

Clinical Rheumatology
|June 28, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuum of HIV care of newly diagnosed individuals in Israel, 2011-2015: a population-based cohort study.

International journal of STD & AIDS·2020
Same author

The diagnostic value of 14-3-3η protein levels in patients with rheumatoid arthritis.

Best practice & research. Clinical rheumatology·2019
Same author

Decrease in 14-3-3η protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib.

Pharmacological research·2018
Same author

Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience.

Lupus·2017
Same author

Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature.

Immunologic research·2014
Same author

The effect of ongoing blood loss on human serum concentrations of perfluorinated acids.

Chemosphere·2014
Same journal

Serum ferritin as a predictor of major adverse cardiovascular events in Takayasu arteritis: a two-center retrospective cohort study.

Clinical rheumatology·2026
Same journal

Inverse association between metabolic dysfunction-associated steatotic liver disease and incident rheumatoid arthritis in middle-aged adults with chronic hepatitis B.

Clinical rheumatology·2026
Same journal

Extension of cytokines' role in Behcet's disease associated peripheral neuropathy.

Clinical rheumatology·2026
Same journal

Renal osteodystrophy with near-complete bilateral sacroiliac ankylosis: a bat-like pelvic configuration on CT.

Clinical rheumatology·2026
Same journal

Serum exosomal tRNA-derived small RNAs as diagnostic biomarkers for primary Sjögren's syndrome: a combined model with autoantibodies.

Clinical rheumatology·2026
Same journal

Monosodium urate crystals induce lytic macrophage death partially dependent on both pyroptosis and necroptosis.

Clinical rheumatology·2026
See all related articles

Systemic sclerosis patients receiving high-dose intravenous immunoglobulin (IVIg) showed significant skin score improvement. Further research is needed to confirm IVIg

Area of Science:

  • Rheumatology
  • Immunology

Background:

  • Systemic sclerosis (SSc) is a progressive autoimmune disease characterized by skin thickening.
  • Limited treatment options exist for rapidly deteriorating SSc, particularly skin manifestations.

Observation:

  • Three SSc patients with severe skin disease received high-dose intravenous immunoglobulin (IVIg).
  • Two patients completed six monthly IVIg courses without adverse events or disease progression.
  • One patient experienced renal failure after three courses, later succumbing to sepsis.

Findings:

  • All patients demonstrated a significant reduction in modified Rodnan skin thickness scores post-IVIg treatment.
  • No changes in PM-Scl antibody titers were observed during the study.
  • High-dose IVIg may be a potential treatment for severe SSc skin involvement.

Related Experiment Videos

Implications:

  • Intravenous immunoglobulin (IVIg) shows promise for managing rapidly progressive skin disease in SSc.
  • Further investigation into optimal dosing, long-term safety, and patient selection for IVIg in SSc is warranted.
  • This study highlights a potential therapeutic avenue for SSc patients with significant cutaneous manifestations.